BETABiohacksAI is a research tool for informational purposes only. All outputs are computational hypothesis candidates — not confirmed mechanisms, not medical advice, and not a substitute for professional medical judgment. Independent experimental validation is always required.
BiohacksAI is an evolving scientific literature platform. New compounds and evidence are indexed continuously.
B
○

Avapritinib

A tyrosine kinase receptor inhibitor that targets mutants of PROTO-ONCOGENE PROTEIN KIT and PLATELET-DERIVED GROWTH FACTOR ALPHA RECEPTOR.

246+ PubMed studies analyzed · 4 RCTs · Evidence Score: 48.6

Research Domains

Avapritinib has been studied across 11 research domains including 🔬 Oncology, 🦠 Gut & Microbiome, 🫘 Kidney, 🛡️ Immunity, 🫁 Liver & Detox. The primary research focus is 🔬 Oncology with 48% of studies addressing this area.

Similar Compounds by Shared Targets

The following compounds share molecular targets with Avapritinib, based on binding affinity data from BindingDB and ChEMBL. Sorted by shared target overlap.

su
3 shared targets
mebendazole
2 shared targets
verubulin
2 shared targets
ag1295
2 shared targets
sunitinib
2 shared targets
semaxanib
4 shared targets
tyrphostin
2 shared targets
sotuletinib
2 shared targets
pexidartinib
3 shared targets
ilorasertib
4 shared targets
Loading evidence profile...

This evidence profile for Avapritinib is generated deterministically from 246 PubMed-indexed studies. All data is corpus-verified with Merkle proofs. BiohacksAI does not provide medical advice. Always consult a healthcare professional before starting any supplement regimen.

Data source: PubMed/MEDLINE (NLM). Corpus version: current. Patent pending (EVE-PAT-2026-001). © 2026 Organiq Sweden AB.